title: Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer.
abstract: OBJECTIVE
  To assess whether disodium pamidronate (DP) once started should be given life-long in women with lytic bone metastases.
  
  
  METHODS
  One hundred and three women with breast cancer who had at least one osteolytic lesion received 180 mg of DP as a 2-h intravenous infusion given every 4 weeks for a life-time, following local radiotherapy. After six cycles, 26 out of 103 patients (25%) refused to continue their bisphosphonate-treatment. Thus two groups were constituted: non-stop (group A) and premature discontinued (group B). The new skeletal complication free survival (NSCFS) was the primary endpoint verified during extramural review. Performance status, pain-score and biochemical markers were secondary endpoints.
  
  
  RESULTS
  Generally DP was well tolerated. At 36 months, the proportion of patients having had any skeletal complication was 54.5 and 84.6% in group A and B, respectively. The median time of NSCFS was apparently longer for group A. In group A, the pain score and the ECOG status were significantly lower, while the overall survival appeared to be longer. Multivariate analysis revealed age, nodal status and interruption of treatment as prognostic factors to NSCFS, with relative risk 1.05, 2.3 and 1.5 respectively.
  
  
  CONCLUSIONS
  Data concerning the suspension of new skeletal complications, as well as the apparent improvement of overall survival, pain score and ECOG status, suggest that the pamidronate-treatment should not be stopped once started. These results should be confirmed in a randomised trial.
authors.affiliation: Department of Radiology, Areteion University Hospital of Athens, Athens, Greece. vkouloul@cc.ece.ntua.gr
authors.forename: Vassilis E
authors.initials: VE
authors.lastname: Kouloulias
authors.forename: John R
authors.initials: JR
authors.lastname: Kouvaris
authors.forename: Kyriaki
authors.initials: K
authors.lastname: Mystakidou
authors.forename: Maria N
authors.initials: MN
authors.lastname: Varela
authors.forename: John
authors.initials: J
authors.lastname: Kokakis
authors.forename: Kyriaki
authors.initials: K
authors.lastname: Pistevou-Gombaki
authors.forename: Myrsini
authors.initials: M
authors.lastname: Balafouta
authors.forename: Costas
authors.initials: C
authors.lastname: Gennatas
authors.forename: Lambros J
authors.initials: LJ
authors.lastname: Vlahos
mesh_terms: D000328:Adult; D001859:Bone Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006115:Greece; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000209:etiology / Q000503:physiopathology; D000077268:Pamidronate; D010349:Patient Compliance
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate